Medico Plus Pharmaceutical Import Profile — Congo Dr (DGFT 2022–2026)

Name: Medico Plus Pharmaceutical Import Records from India — 4 Products, $237.6K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Medico Plus — Pharmaceutical Importer Profile (2026) | 4 Products, $237.6K Trade | TransData Nexus

Medico Plus

Pharmaceutical Importer · Congo Dr · Advanced Antibiotics Focus · $237.6K Total Trade · DGFT Verified

Medico Plus is a pharmaceutical importer based in Congo Dr with a total trade value of $237.6K across 4 products in 4 therapeutic categories. Based on 43 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Medico Plus sources from 9 verified Indian suppliers, with Axelia accounting for 44.5% of imports.

Medico Plus — Import Portfolio & Supplier Network

Medico Plus import network — 4 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Medico Plus?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Axelia	$4.3M	428	44.5%
Arco Pharma Private Limited	$2.2M	192	22.3%
Synmex Pharma Private Limited	$1.8M	290

What Formulations Does Medico Plus Import?

Formulation	Value	Ships
Zebu + ( paracetamol BP 325 MG +	$327.9K	10
Zebu + ( paracetamol b.p. 325 MG + diclofenac sodium b.p. 50 MG + caffeine anhy b.p. 30 MG tablet)	$244.2K	10
Zebu + ( paracetamol b.p. 325 MG +	$198.0K	7
Zebu paracetamol BP 325 MG diclofenac sodium BP 50 MG caffeine anhy BP 30 MG	$140.4K	4
Dicdol tablets (paracetamol.325MG +	$139.2K	4
Cefix-200 tablets (Each film coated	$126.0K	3
Tramadol hydrochloride injection(100MG/2ML) Each 2ML ampoule contains tramadolhydrochloride BP 100MG, water for	$101.1K	26
Zebu + paracetamol b.p. 325 MG +	$95.7K	4
Bien manger (cyproheptadine tablet b.p.	$91.3K	6
Cefix tablets 400MG (Each film coated	$89.4K	6
Medico plus action diclofenac sodium bp50 MG + paracetamol BP 325 MG + chlorphenamine maleate BP 4 MG magnesium	$84.2K	4
Zebu + ( paracetamol b.p. 325 MG + diclofenac sodium b.p. 50 MG + caffeine anhyb.p. 30 MG tablet) ( 148500 x10x1x10)	$77.0K	3
Paracetamol tablets (paracetamol	$73.1K	2
Diclofenac 50 tablets (diclofenac	$72.6K	3
Medico plus action diclofenac sodium BP 50 MG paracetamol BP 325 MG chlorphenamine maleate BP 4 MG magnesium	$71.2K	4

Medico Plus imports 558 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 4 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Norfloxacin	Advanced Antibiotics	$97.6K	21	1.2%	11
2	Diazepam	CNS & Psychiatric	$78.0K	16	1.0%	14
3	Aminophylline	Respiratory & OTC	$32.9K	4	0.6%	13
4	Levamisole	Antimalarial & Antiparasitic	$29.0K	2	1.1%	10

Medico Plus imports 4 pharmaceutical products across 4 categories into Congo Dr totaling $237.6K.

Medico Plus — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Medico Plus is a pharmaceutical importer based in the Democratic Republic of Congo (DRC), specializing in the procurement of finished pharmaceutical formulations from international suppliers. The company plays a pivotal role in the DRC's pharmaceutical distribution network, ensuring the availability of essential medications across the country. While specific details about its parent company and corporate structure are not publicly disclosed, Medico Plus's operations are integral to the healthcare supply chain in the DRC.

2Distribution Network

Medico Plus's distribution network encompasses multiple warehouse locations strategically situated to facilitate efficient logistics and timely delivery of pharmaceutical products throughout the DRC. The company's logistics capabilities are designed to navigate the diverse and often challenging terrains of the country, ensuring that medications reach both urban centers and remote areas. This extensive geographic coverage underscores Medico Plus's commitment to enhancing healthcare accessibility across the DRC.

3Industry Role

Within the DRC's pharmaceutical supply chain, Medico Plus functions primarily as a wholesaler and distributor. By importing finished pharmaceutical formulations and distributing them to various healthcare facilities, pharmacies, and other stakeholders, the company ensures a steady supply of essential medications. This role is crucial in maintaining the integrity and reliability of the pharmaceutical supply chain in the DRC.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Medico Plus

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Medico Plus's sourcing strategy exhibits a high degree of concentration, with a significant portion of its pharmaceutical imports originating from India. This focused approach suggests a strategic choice to leverage India's robust pharmaceutical manufacturing capabilities and cost-effectiveness. The company's reliance on a select group of Indian suppliers indicates a stable and well-established relationship, which is essential for ensuring consistent product quality and supply reliability. However, this concentration also presents potential risks, such as exposure to supply chain disruptions in India or changes in trade policies.

2Supply Chain Resilience

Medico Plus's supply chain resilience is bolstered by its partnerships with multiple Indian suppliers, providing a degree of diversification that mitigates the risks associated with sole sourcing. The company's import data reveals a diverse range of pharmaceutical formulations, indicating a broad product portfolio that caters to various therapeutic needs. While specific details about backup suppliers and shipping routes are not publicly available, the company's established relationships with Indian manufacturers suggest a level of preparedness to address potential supply chain disruptions. Ensuring compliance with international quality standards, such as Good Manufacturing Practice (GMP), is crucial for maintaining the integrity of the supply chain.

Importing Pharmaceuticals into Congo Dr — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Congo Dr

1Regulatory Authority & Framework

The Congolese Pharmaceutical Regulatory Authority (ACOREP) is the primary body responsible for regulating pharmaceutical activities in the DRC. ACOREP oversees the importation, distribution, and marketing of pharmaceutical products, ensuring compliance with national health standards. The regulatory framework governing pharmaceutical imports includes requirements for import licenses, quality control measures, and adherence to international standards. While ACOREP has been in the process of assuming responsibilities from the Directorate of Pharmacy and Medicine (DPM) since March 2020, as of December 2025, the transition is still ongoing.

2Import Licensing & GMP

Importers in the DRC must obtain an import license from an authorized commercial bank and undergo a pre-shipment inspection by the Congolese Control Office (OCC) for shipments valued over $2,500. While Good Manufacturing Practice (GMP) certification is officially required, enforcement is often inconsistent; a Certificate of Pharmaceutical Product (CPP) is a critical document. For quality control, initial screening is conducted locally using methods like the GPHF Minilab, with more comprehensive analysis performed at WHO-prequalified laboratories abroad.

Quality & Labeling

Medico Plus — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Medico Plus's focus on importing advanced antibiotics, central nervous system (CNS) and psychiatric medications, and respiratory and over-the-counter (OTC) products aligns with the therapeutic needs prevalent in the DRC. The substantial import values of products like Norfloxacin, Diazepam, Aminophylline, and Levamisole indicate a strategic emphasis on addressing common health concerns such as infections, mental health disorders, and respiratory conditions. This product strategy is driven by market demand and the necessity to provide essential medications to the population.

2Sourcing Profile

Medico Plus's sourcing strategy is centered on procuring generic pharmaceutical products, primarily from India, known for its cost-effective manufacturing and a wide range of generic medications. The company's preference for finished pharmaceutical formulations over raw active pharmaceutical ingredients (APIs) suggests a focus on ready-to-market products that can be swiftly distributed within the DRC. India's established pharmaceutical industry and favorable trade relations with the DRC make it a strategic sourcing partner for Medico Plus.

3Market Positioning

Seller's Guide — How to Become a Supplier to Medico Plus

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with Medico Plus, especially those offering a diverse range of generic pharmaceutical products that align with the therapeutic areas currently emphasized by the company. Identifying and addressing any gaps in Medico Plus's current sourcing, such as emerging therapeutic needs or product shortages, can provide avenues for new suppliers to enter the market.

2Requirements & Qualifications

Indian exporters aiming to supply Medico Plus and the DRC market must obtain GMP certification recognized by international bodies, such as the World Health Organization (WHO) or the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Additionally, compliance with the DRC's import licensing requirements, including obtaining an import license and undergoing pre-shipment inspections, is mandatory. Ensuring that products meet the DRC's quality control standards and labeling requirements is also essential for market entry.

3How to Approach

Frequently Asked Questions — Medico Plus

What products does Medico Plus import from India?

Medico Plus imports 4 pharmaceutical products across 4 categories. Top imports: Norfloxacin ($97.6K), Diazepam ($78.0K), Aminophylline ($32.9K), Levamisole ($29.0K).

Who supplies pharmaceuticals to Medico Plus from India?

Medico Plus sources from 9 verified Indian suppliers. The primary supplier is Axelia (44.5% of imports, $4.3M).

What is Medico Plus's total pharmaceutical import value?

Medico Plus's total pharmaceutical import value from India is $237.6K, based on 43 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Medico Plus focus on?

Medico Plus imports across 4 categories. The largest: Advanced Antibiotics (41.1%), CNS & Psychiatric (32.8%), Respiratory & OTC (13.9%).

Get Full Medico Plus Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.